Summary & Overview
HCPCS J9042: Brentuximab Vedotin Injection, 1 mg
HCPCS Level II code J9042 denotes a 1 mg unit of brentuximab vedotin, an injectable antineoplastic agent used in oncology infusion settings. Nationally, billing for high-cost oncology biologics like brentuximab influences site-of-care decisions, patient cost-sharing, and payer coverage policies. This code is essential for accurate claims, provider reimbursement, and drug utilization tracking in outpatient infusion centers and hospital outpatient departments.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of brentuximab vedotin, typical sites of service, and what to expect in claims workflows. The publication provides benchmarks for unit reporting and discusses common billing considerations tied to injectable chemotherapy codes.
The report also summarizes policy and coding updates relevant to HCPCS Level II billing for antineoplastic agents, outlines documentation elements typically associated with oncology infusions, and highlights areas where payers commonly apply medical necessity and prior authorization criteria. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J9042 represents an injection of brentuximab vedotin, 1 mg. This drug is an antibody–drug conjugate used in oncology for targeted treatment of certain hematologic malignancies. The service type is injectable chemotherapy/antineoplastic agent. The typical site of service is an outpatient oncology infusion center or hospital outpatient department where intravenous or intrathecal antineoplastic agents are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 55-year-old with relapsed or refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma receiving outpatient infusion therapy. Brentuximab vedotin, billed as J9042 per milligram, is administered intravenously in an oncology infusion suite or hospital outpatient infusion center. The workflow begins with oncologist assessment and order entry specifying total milligrams required; pharmacy compounds the weight-based dose and performs verification; an infusion nurse performs baseline vitals, verifies consent and allergies, confirms central or peripheral IV access, and administers premedications if indicated. The medication is infused over the manufacturer-recommended time with monitoring for infusion-related reactions, neuropathy, neutropenia, and other adverse effects. Post-infusion documentation includes drug lot, amount administered in milligrams, site of service, applicable modifier(s), and any adverse events. Typical sites of service are outpatient hospital infusion center, physician office oncology infusion suite, or ambulatory infusion clinics.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug or biological quantity discarded/not administered to patient | Use when part of the prepared vial(s) is discarded and must be reported separately from administered units. |